33 results about "Desflurane" patented technology

A therapy utilizing inhaled anesthetic agents (such as desflurane, sevoflurane, isoflurane, or xenon) for the sedation of patients outside of the immediate perioperative space such as in the medical intensive care unit (MICU) and the surgical intensive care unit (SICU). The therapy includes controlled delivery of volatile anesthetic agents to patients undergoing ventilatory support on an ICU ventilator over extended periods of time. A system which provides for the delivery of anesthetic agents includes an anesthetic agent vaporizer element, an anesthetic agent reflector, and a plug-in cassette which contains both a cartridge housing liquid phase volatile anesthetic agent and an anesthetic vapor scrubbing medium.

A therapy utilizing inhaled anesthetic agents (such as desflurane, sevoflurane, isoflurane, or xenon) for the sedation of patients outside of the immediate perioperative space such as in the medical intensive care unit (MICU) and the surgical intensive care unit (SICU). The therapy includes controlled delivery of volatile anesthetic agents to patients undergoing ventilatory support on an ICU ventilator over extended periods of time. A system which provides for the delivery of anesthetic agents includes an anesthetic agent vaporizer element, an anesthetic agent reflector, and a plug-in cassette which contains both a cartridge housing liquid phase volatile anesthetic agent and an anesthetic vapor scrubbing medium.

Disclosed and claimed herein are devices and method for the recovery of one or more anesthetic agents after they have been exhaled from a patient undergoing surgery and before they have been vented to the atmosphere. Typical anesthetic agents include, but are not limited to, isoflurane, desflurane, sevoflurane, and the like. Recovery of the anesthetic agents should result in numerous benefits including, but not limited to, reduction of their production costs, protection of the environment, and the like.

The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and / or periodic administration are contemplated.

A process for preparing fluorinated ethers, such as desflurane, comprises reacting the corresponding chlorinated ether, such as isoflurane, with anhydrous hydrogen fluoride in the vapor phase in the presence of chromia catalyst. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

The invention discloses a desflurane evaporation tank capable of automatically detecting the liquid level, and relates to the technical field of desflurane evaporation tanks. The desflurane evaporation tank comprises a bearing assembly and a sealing assembly, and the left side of the upper end of the bearing assembly is provided with an evaporation assembly; the evaporation assembly comprises an evaporation tank, a visible window, an automatic liquid level monitor, a heating pipe, a heat preservation sleeve, a condensate water guide pipe and a condensate water collecting tank, and the visible window is arranged in the middle of the front end of the evaporation tank. Through a limiting block arranged in the outer side of the top cover and a limiting groove formed in the inner side of a tight ring, the tight ring can rotate clockwise at the upper end of a sealing ring through pushing of an electric push rod, when the top cover is closed, the limiting block is just embedded into the limiting groove, and then through rotation of the tight ring, the limiting block is rotated to be clamped into the limiting groove, so that the effect of closing and fixing the top cover and the evaporation tank body is achieved, the tightness of the closing mode is better, and the situation of gas leakage of the evaporation tank body is effectively avoided.

A pressure-resistant tank for liquids includes a plurality of differently shaped diecast parts (1, 2) made of a first aluminum alloy (cast alloy). The diecast parts (1, 2) are connected by means of a closed weld seam welded with an electron beam with the use of a second aluminum alloy (wrought alloy). The second aluminum alloy has especially a hydrogen content of less than 0.2 mL per 100 g of wrought alloy. The tank for liquids is especially an anesthetic tank and the anesthetic is desflurane.

The invention relates to methods of treating or preventing organophosphate poisoning in a subject in need thereof, comprising administering to the subject isoflurane, enflurane, halothane, sevoflurane, desflurane, xenon or argon in a therapeutically effective amount.

The invention discloses a UV (Ultraviolet) curing fluorine-silicon release agent and a preparation method thereof. The structure of the UV curing fluorine-silicon release agent disclosed by the invention is shown as follows, wherein R1 is CnH2n+1, and n is equal to 1-9; R2 is one of the structural formulas as shown in the specification; R3 is C2H4CnF2nC2h4, and n is equal to 1-9; R4 is C2H4Rf, and Rf is desflurane group or perfluoroalkyl; and x is equal to 1-5000, y is equal to 1-5000, z is equal to 0-5000, and w is equal to 1-5000. According to the UV curing fluorine-silicon release agent disclosed by the invention, the preparation method is simple, and the problems such as high-temperature curing and cheap catalysts can be solved. The structural formula is as shown in the specification.

An azeotrope comprising desflurane (CF3CFHOCF2H) and hydrogen fluoride (HF). The azeotrope can be prepared by fractionally distilling a crude mixture of desflurane and HF. Purer desflurane can be readily and easily separated from the azeotrope. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

A process for preparing 2-difluoromethoxy-1,1,1,2-tetrafluoroethane (desflurane) comprising the following steps: (a) providing a first mixture comprising desflurane and 2,2-dichloro-1,1,1-trifluoroethane (R-123); (b) adding water to the first mixture to form a second mixture; and (c) fractionally distilling the second mixture to yield a desflurane product purer in R-123 than said the mixture. Also described is a purified desflurane product prepared by the process, and intermediate products comprising water added to a mixture of desflurane and R-123.

The invention discloses an ECD determination method for residual quantity of N-(3-chloro-5-(trichloromethyl)pyridyl-2-methyl)-2,3,5,6-tetrafluoro-4-methoxybenzamide in vegetables and fruits. The ECD determination method comprises the following steps: homogenizing by using acetonitrile or an acetonitrile solution containing 1% acetic acid to extract residual desflurane bacteria amide in a sample; after dispersing and purifying an extract by using ethidene diamine-N-propylsilane (PSA) and octadecylsilane bonded phase (C18) matrix, determining by using a gas chromatography-electron capture detector (GC-ECD); quantifying by an external standard method. By the ECD determination method, the average recycling rate is 93.3-98.3%, the average relative standard deviation (RSD) is 4.1-6.5%, and the determination limit is lower than 3.16 [mu]g / kg; the ECD determination method has the advantages of simple, convenient and rapid operation, high sensitivity, good repeatability and accurate quantification; by the ECD determination method, a technical requirement on a uniform residue limit of 0.01mg / kg can be met; a powerful technical support is provided for guaranteeing food safety of people in China and healthy development of export trade.

A process for preparing fluorinated ethers, such as desflurane, comprises reacting the corresponding chlorinated ether, such as isoflurane, with anhydrous hydrogen fluoride in the vapor phase in the presence of chromia catalyst. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

The present invention provides a continuous process for the production of 1,2,2,2-tetrafluoroethyl difluoromethyl ether (desflurane) which comprises feeding continuously optimum molar quantities of 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether (CF3CHClOCHF2, Isoflurane) and anhydrous hydrogen fluoride, in a reactor in the vapor phase over a fluorination catalyst system comprising a metal pentahalide absorbed on a supporting substrate at a temperature ranging from 100° C. to 180° C., and separating 1,2,2,2-tetrafluoroethyl difluoromethyl ether (desflurane) continuously from the reactor. The process of the present invention enables continuous removal of desflurane product thereby minimizing co-production of byproducts and resulting in high conversion efficiency and yield of desflurane.

The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic dissolved in a solution comprising an extractive solvent, e.g., DMSO or NMP, in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered as a regional anesthesia to a subject to anesthetize a portion the subject prior to a surgery, hi certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, or mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and / or periodic administration are contemplated.